Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in ...

Mirum Pharma receives Health Canada authorization for maralixibat to treat cholestatic pruritus in patients with Alagille syndrome: Toronto Saturday, February 7, 2026, 15:00 Hrs [ ...

Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral ...

BoomRx, the fastest-growing national pharmaceutical technology platform that simplifies prescription sourcing and fulfillment, today announced the availability of an oral liquid testosterone ...

OPKO Health, Inc. (NASDAQ: OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO), and Entera Bio Ltd. (NASDAQ: ENTX) (Entera or the Company), a leader in the development of oral peptide and ...

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

News and commentary from the endocrinology world ...

Exploring the vital link between healthcare costs and patient affordability in India's evolving medical landscape.

Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...

Researchers at Queen Mary University of London have led the clinical development of the first non-integrase strand-transfer inhibitor (INSTI) single tablet treatment for HIV, among growing concern for ...

The compounded GLP-1 space landed in the Washington spotlight late last week after nearly a year of little news in the second ...